Two Early Studies Evaluating Potential First-in-Class CELMoD ™ Agent Golcadomide for the Treatment of Non-Hodgkin Lymphomas Presented at ASH 2023

Phase 1b DLBCL-001 study reinforces promising activity and combinability of golcadomide with R-CHOP in patients with previously untreated aggressive B-cell lymphoma Phase 1/2 CC-99282-NHL-001 study demonstrate s activity and combinability with...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials